- Home
- XXII vs ACXP Comparison
XXII vs ACXP Comparison
Compare XXII & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XXII
- ACXP
- Stock Information
- Founded
- XXII 1998
- ACXP 2017
- Country
- XXII United States
- ACXP United States
- Employees
- XXII N/A
- ACXP N/A
- Industry
- XXII Medicinal Chemicals and Botanical Products
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- XXII Health Care
- ACXP Health Care
- Exchange
- XXII Nasdaq
- ACXP Nasdaq
- Market Cap
- XXII 7.0M
- ACXP 8.4M
- IPO Year
- XXII N/A
- ACXP 2021
- Fundamental
- Price
- XXII $0.74
- ACXP $0.35
- Analyst Decision
- XXII
- ACXP Strong Buy
- Analyst Count
- XXII 0
- ACXP 2
- Target Price
- XXII N/A
- ACXP $10.00
- AVG Volume (30 Days)
- XXII 288.8K
- ACXP 233.4K
- Earning Date
- XXII 05-13-2025
- ACXP 05-13-2025
- Dividend Yield
- XXII N/A
- ACXP N/A
- EPS Growth
- XXII N/A
- ACXP N/A
- EPS
- XXII N/A
- ACXP N/A
- Revenue
- XXII $23,869,000.00
- ACXP N/A
- Revenue This Year
- XXII $22.41
- ACXP N/A
- Revenue Next Year
- XXII $76.35
- ACXP N/A
- P/E Ratio
- XXII N/A
- ACXP N/A
- Revenue Growth
- XXII N/A
- ACXP N/A
- 52 Week Low
- XXII $0.70
- ACXP $0.30
- 52 Week High
- XXII $140.40
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- XXII 32.55
- ACXP 37.87
- Support Level
- XXII $0.72
- ACXP $0.34
- Resistance Level
- XXII $0.77
- ACXP $0.36
- Average True Range (ATR)
- XXII 0.06
- ACXP 0.02
- MACD
- XXII -0.01
- ACXP -0.00
- Stochastic Oscillator
- XXII 5.25
- ACXP 5.19
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.